SMARCA4 and non-small cell lung carcinoma: [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient  Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus  Chemotherapy and Chemotherapy].